Rosetta Genomics Announces Compliance with Continued Listing Requirements of The NASDAQ Capital Market
News Jun 07, 2012
Rosetta Genomics has announced that the NASDAQ Listing Qualifications Staff has determined that the Company is in compliance with the $2.5 million stockholders' equity requirement for continued listing on The NASDAQ Capital Market® as set forth in NASDAQ Listing Rule 5550(b)(1).
NASDAQ will continue to monitor the Company's periodic reports to confirm the Company's ongoing compliance with the stockholders' equity requirement.
"As a result of our recently announced registered direct offerings, we were successful in increasing stockholders' equity beyond NASDAQ's listing requirement. We are very pleased to have regained compliance with the rule," said Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.
Berlin continued, "With this determination by NASDAQ, we are now in compliance with the continued listing requirements of The NASDAQ Capital Market."
Genomics Researchers Showcase their Applications of Droplet Digital PCR at ASHG 2017 Annual MeetingNews
The sensitivity and reliability of Droplet Digital PCR will be showcased in over a dozen presentations at the American Society of Human Genetics (ASHG) 2017 Annual Meeting.READ MORE
BC Platforms Announces Collaborations in Multiple Sclerosis ResearchNews
Company's technology and research platforms used to better understand genetic basis of MS.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018